A review of abstracts on pneumonia published at abstract books of the 24th Russian Congress on Respiratory Diseases and the 24th Annual Congress of the European Respiratory Society

Community-acquired pneumonia (CAP) is a widespread acute respiratory infectious disease. The aim of this article was to analyze recent achievements in diagnosis, management and prevention of CAP. Methods. A search of abstracts on pneumonia published at abstract books of the 24th Russian Congress on Respiratory Diseases and the 24^th Annual Congress of the European Respiratory Society was performed using "community acquired pneumonia" keyword. Results. A total of 28 Russian and 92 European abstracts were found. The majority of abstracts were dealt with etiology and pathogen identification methods; rapid tests (urine antigen test for Streptococcus pneumoniae and polymerase chain reaction for identification of bacteria and viruses) are actively implementing in the clinical practice. Data on antibacterial resistance of typical and atypical pathogens and data on pathogen influence on the outcome of CAP have also been shown.

European investigators paid particular attention to nosocomial pneumonia. Clinical scales, both classic (CRB-65 / CURB-65 criteria IDSA / ATS, etc.) and novel, for assessment of CAP severity and prognosis were introduced. Clinical evaluation of the patient with CAP and use of instrument diagnostic methods were also presented. Predictors of poor outcome were determined based on inpatient and outpatient data analysis. In some studies, investigations on routinely used biomarkers and new molecules and reactive oxygen species metabolism were described. Several papers have been published about CAP and comorbidity including cardiovascular diseases, COPD, diabetes, etc. Empirical antibiotic therapy and its change in randomized clinical trials both in the CAP and in hospital acquired pneumonia and ventilator-associated pneumonia, non-antibacterial and intensive therapies of pneumonia were widely discussed. An analysis of quality of care was done in some Russian and European abstracts. Conclusion. Pneumonia today is a crucially important problem involving a wide range of specialists.

1. ​Bilichenko T., Argunova A., Antonova O. et al. Pneumococcal pneumonia frequency in adult patients at three Russian Regions. Eur. Respir. J. 2014; 44 (Suppl. 58): 1057.

2. Menéndez R., Torres A., España P.P. et al. LATE-BREAKING ABSTRACT: Pneumococcal serotypes causing community-acquired pneumonia (CAP) among hospitalized adults in Spain using a new urinary antigen detection (UAD) test. The CAPA study. Eur. Respir. J. 2014; 44 (Suppl. 58): 1810.

3. ​Torres A., Bouza E., Pallarés R. et al. Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010–2013). Eur. Respir. J. 2014; 44 (Suppl. 58): 1050.

4. ​Blasi F., Aliberti S., Mantero M. et al. PICTURE: Clinical pattern and pneumococcal infections in patients with community-acquired pneumonia (CAP) admitted to emergency department. Eur. Respir. J. 2014; 44 (Suppl. 58): 2545.

5. ​Aoshima M., Ariyoshi K., Asoh N. The two years of prospective hospital based multicenter adult pneumonia surveillance in Japan; the final year report of APSG-Japan. Eur. Respir. J. 2014; 44 (Suppl. 58): 1054.

6. ​Yoshii Y., Shimizu K., Morozumi M. et al. Multiplex real-time polymerase chain reaction is useful in diagnosing pathogens causing community-acquired pneumonia including atypical bacteria and viruses. Eur. Respir. J. 2014; 44 (Suppl. 58): 4935.

7. ​Gabrilovich M., Quinter C., Bacheller C. et al. Utilization of target enriched multiplex PCR for detection of pantonvalentine leukocidin in necrotizing pneumonia complicating influenza A. Eur. Respir. J. 2014; 44 (Suppl. 58): 2497.

8. ​Ivanov V.V., Kharitonov M.A., Zhurkin M.A. et al. Current treatment of lower respiratory tract infection. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 214 (in Russian).

9. ​Ivanov V.V., Kharitonov M.A., Rudakov Yu.V. et al. Current spectrum of pathogens in viral and bacterial community-acquired pneumonia in military population. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 215 (in Russian).

10. ​Montull B., Menendez R., Mendez R. et al. The impact of mixed etiology in community acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 4649.

11. ​Berce V., Unuk S., Duh D. et al. Viral infections of the lower respiratory tract and the presence of pneumonia in preschool children. Eur. Respir. J. 2014; 44 (Suppl. 58): 391.

12. ​Picot V., Messaoudi M., Telles J.N. et al. Preliminary results of the pilot pneumonia multicentric study in the GABRIEL network for etiological agents identification. Eur. Respir. J. 2014; 44 (Suppl. 58): 1052.

13. ​Skachkova M.A., Popkova N.I., Korneev V.G. et al. Etiology of community-acquired pneumonia in children. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 197–198 (in Russian).

14. ​Panina O.C., Chernenkov Yu.V., Arkhangel'skiy S.M. et al. An importance of etiology monitoring for a choice of starting therapy in prenatal pneumonia. V kn.: Sbornik trudov XXIV Natsional'nogo kongressa po boleznyam organov dykhaniya. Moscow: Dizaynpress; 2014: 197 (in Russian).

15. ​Bisenova N., Yergalieva A. Monitoring of antimicrobial resistance respiratory strains of streptococcus pneumoniae. Eur. Respir. J. 2014; 44 (Suppl. 58): 2555.

16. ​Hurtado E.J.S., Fern#ández M.J.G., Fern#ández D.G. et al. Relationship between bacterial sensivity pattern and hospital antibiotic consumption,in patients with community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2575.

17. ​Rehman T., Somani V., McGeary C. et al. Microbiology and outcomes in patients with pneumonia in an English Hospital. Eur. Respir. J. 2014; 44 (Suppl. 58): 3642.

18. ​Spoorenberg S., Bos W.J., Heijligenberg R. et al. Microbial aetiology, outcomes, and costs of hospitalization for community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 203.

19. ​Armbruster K., Meyer C., Kemp M. et al. Clinical and bacterial characteristics in Danish adults with pleural empyema. Eur. Respir. J. 2014; 44 (Suppl. 58): 4931.

20. ​Braeken D., Franssen F., Schütte H. et al. Microbial etiology of community-acquired pneumonia and it's relation with ICS use in patients with COPD – Results from the German competence network CAPNETZ. Eur. Respir. J. 2014; 44 (Suppl. 58): 2476.

21. ​Kurai D., Saraya T., Ishii H. et al. Respiratory viral infections in community-acquired pneumonia and exacerbation of COPD: One year survey at a Japanese university hospital. Eur. Respir. J. 2014; 44 (Suppl. 58): 2563.

22. ​Shafiek H., Merino J., Fiorentino F. et al. LATE-BREAKING ABSTRACT: A novel method to detect infection in COPD exacerbations: the electronic nose. Eur. Respir. J. 2014; 44 (Suppl. 58): 2566.

23. ​Prina E., Ranzani O.T., Polverino E. et al. Pseudomonas, enterobacteriaceae ESBL positive and staphylococcus MRSA: When to suspect them in CAP? Eur. Respir. J. 2014; 44 (Suppl. 58): 2475.

24. ​Ghodousi A., Omrani M., Feizabadi M.M. Methicillin-resistant staphylococcus aureus: The most prevalent cause of ventilator associated pneumonia in Tehran hospitals. Eur. Respir. J. 2014; 44 (Suppl. 58): 2558.

25. ​Almomani B., Al-Gharaibeh R., Al-Mahasneh F. et al. Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality. Eur. Respir. J. 2014; 44 (Suppl. 58): 2071.

26. ​Abreu S., Silveira I., Ferreira J.P. et al. Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy. Eur. Respir. J. 2014; 44 (Suppl. 58): 4691.

27. ​Ruiz L.A., Castro S., Gómez A. et al. Community adquired legionella pneumophila pneumonia in elderly patients. Eur. Respir. J. 2014; 44 (Suppl. 58): 2474.

28. ​Herkt C., Marsico A., Bertrams W. et al. Differentially expressed miRNAs after Legionella pneumophila infection of human macrophages Eur. Respir. J. 2014; 44 (Suppl. 58): 4943.

29. ​Lacerda C., Rolo R., Majar M. Pseudomonas aeruginosa pneumonia in the community. Eur. Respir. J. 2014; 44 (Suppl. 58): 2581.

30. ​Ferrer M, Rosa F., Fernandez L. et al. ICU acquired pneumonia due to pseudomonas aeruginosa with and without multidrug resistance. Eur. Respir. J. 2014; 44 (Suppl. 58): 2078.

31. ​Lie N., Heddema E., Linssen C. A new 'bird' in town; severe pneumonia as a new zoonotic disease transmitted by guinea pigs. Eur. Respir. J. 2014; 44 (Suppl. 58): 2522.

32. ​Lohr M., Prohl A., Ostermann C. et al. Parachlamydia acanthamoebae as a respiratory pathogen: Challenge dose titration in a bovine model. Eur. Respir. J. 2014; 44 (Suppl. 58): 2539.

33. ​Ullah S., Khan J.A., Khan A. et al. Assessing decision of inpatient or outpatient care in community acquired pneumonia patients: Results of APT care study. Eur. Respir. J. 2014; 44 (Suppl. 58): 2481.

34. ​Duijkers R., Snijders D., Boersma W. Clinical judgment on top of CURB65-score in predicting 30 days clinical outcome in patients with community acquired pneumonia (CAP) admitted to the hospital. Eur. Respir. J. 2014; 44 (Suppl. 58): 4934.

35. ​Kostadinova V., Miteva D., Radkov Y. et al. In-hospital mortality risk assessment in patients with community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2477.

36. ​Shaymuratov R.I. Use of prognostic scales in community-acquired pneumonia: clinical trials and real-life practice. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 211 (in Russian).

37. ​Miteva D., Kostadinova V., Radkov Y. et al. Comparison of the prognostic value of different severity scales in community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2479.

38. ​G#ünd#üz C., Tasbakan S., Sayiner A. et al. Comparison of health care associated pneumonia and community acquired pneumonia in Turkish Thoracic Society pneumonia database. Eur. Respir. J. 2014; 44 (Suppl. 58): 2524.

39. ​Carrabba M., Colombo A., Zarantonello M. et al. Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised. Eur. Respir. J. 2014; 44 (Suppl. 58): 4687.

40. ​Sanz F., Fernandez-Fabrellas E., Briones M.L. et al. Physiological score SIPF (shock index and hypoxemia) is an accurate predictor of ICU admission in community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4648.

41. ​Dobrykh V.A., Mun I.E., Yu K.V. et al. A relation of symptoms at the onset of acute lower respiratory infections to the further course of the disease. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 216 (in Russian).

42. ​Dobrykh V.A., Mun I.E., Yu K.V. et al. Gender difference in the course of unilateral community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 217 (in Russian).

43. ​Bachurina M.A. An ultrasound examination of pulmonary infiltrate in the diagnosis of pulmonary embolism. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 208 (in Russian).

44. ​Mastuo T., Kitamura A., Nishimura N. et al. Use of a learning tool to enhance the ability of residents to diagnose pneumonia on chest radiographs. Eur. Respir. J. 2014; 44 (Suppl. 58): 4820.

45. ​Zaytseva O.D., Efimova E.G., Sargina A.P. Predicting slowly-resolving course of community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 193–194 (in Russian).

46. ​Makrodimitri S., Melaxroinidou M., Dimakou K. et al. Prognostic factors related with prolong length of stay in community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2516.

47. ​Shaymuratov R.I. Risk factors of death in community-acquired pneumonia: an analysis of 160 cases. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 211–212 (in Russian).

48. ​Brokovskaya V.L. Risk factors of poor outcome in hospitalized patients with community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 194–195 (in Russian).

49. ​Aliberti S., Bellelli G., Belotti M. et al. Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4937.

50. ​Balatskaya I.V., Martynenko T.I., Grebenyuk A.A. et al. Severe pneumonia phenotypes in real clinical practice. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 204 (in Russian).

51. ​Mois#és J., Badia J.R., Ferrer M. et al. Acute respiratory distress syndrome in patients admitted for community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4894.

52. ​Khamitov R.F., Grigor'eva I.V., Pal'mova L.Yu. et al. Outpatient management of community-acquired pneumonia with lethal outcome. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 198–199 (in Russian).

53. ​Zavrazhnov S.P., Kazakov A.I., Balandina E.D. Outpatient treatment of patients with community-acquired pneumonia referred to a TB specialist. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 196 (in Russian).

54. ​Eom J.S., Song W., Ryu D.H. et al. Factors contributing to severe pneumonia in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2014; 44 (Suppl. 58): 2511.

55. ​Badawy M., Mohamed H., Ali H. Evaluation of risk factors of ventilator associated pneumonia on outcome of acute exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2014; 44 (Suppl. 58): 2077.

56. ​Gurina L. Diagnostics of congenital pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 3308.

57. ​Il'enkova N.A., Prokoptseva N.L., Chikunov V.V. et al. Diagnostic markers for differentiation between pneumonia and bronchiolitis in children. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 207–208 (in Russian).

58. ​Postma D., Schuurman J., van Werkhoven C. et al. The neutrophil/lymphocyte ratio in predicting outcome for hospitalized patients with community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2489.

59. ​Echevarria C., Hartley T., Nagarajan T. et al. 30 day mortality and eosinopenia in patients with pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2550.

60. ​Balatskaya I.V., Martynenko T.I., Grebenyuk A.A. et al. Thrombin generation in patients with severe pneumonia and sepsis. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 203–204 (in Russian).

61. ​Savchenko A.A., Dresvyankina L.B., Grinshteyn Yu.I. et al. Chemiluminescent activity of neutrophil granulocytes in sputum and blood of patients with community- acquired non-severe pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 201 (in Russian).

62. ​Savchenko A.A., Dresvyankina L.B., Grinshteyn Yu.I. et al. Luminescent activity of neutrophil granulocytes in patients with community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 202 (in Russian).

63. ​Mirkhaydarov A.M., Farkhutdinov U.R., Farkhutdinov R.R. Free radical-related mechanisms and their correction in community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 209–210 (in Russian).

64. ​Bielosludtseva K., Pertseva T., Kireeva T. et al. Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 2521.

65. ​Bielosludtseva K., Pertseva T. Survival predictors of severe community-acquired pneumonia (CAP): Multivariate analysis of immunological and inflammatory parameters. Eur. Respir. J. 2014; 44 (Suppl. 58): 2529.

66. ​Titova E., Aune M.W., Fonn K. et al. Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation. Eur. Respir. J. 2014; 44 (Suppl. 58): 576.

67. ​Nishiyama A., Tachibana H., Arita M. et al. Serum procalcitonin is useful in differentiating between drug-induced pneumonitis and bacterial pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 3772.

68. ​Almirall J., De la Torre M., Palomera E. et al. Immunoglobulin levels and severity of community-acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 4941.

69. ​Nikitin Yu.E., Nikitin E.N., Shklyaev A.E. A role of the peptide hormone hepcidin in patients with community-acquired pneumonia complicated by anaemia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 192 (in Russian).

70. ​Affara N., Refaat A., Hussein T. et al. Diagnostic accuracy of inflammatory biomarkers in bronchoalveolar lavage from patients with ventilator-associated pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2538.

71. ​Shtepa O., Pertseva T. Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program. Eur. Respir. J. 2014; 44 (Suppl. 58): 3645.

72. ​Shtepa O., Pertseva T. The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 3576.

73. ​James A., Stenberg-Hammar K., Reinius L. et al. Serum YKL-40 is elevated in children with pneumonia and RSV infection. Eur. Respir. J. 2014; 44 (Suppl. 58): 395.

74. ​Holger M.R., Ute K., Tschernig T. et al. Neutralizing the complement component C5a protects against lung injury and extrapulmonary organ injury in pneumococcal pneumonia induced sepsis. Eur. Respir. J. 2014; 44 (Suppl. 58): 1385.

75. ​Jos#é R., Williams A., Sulikowski M. et al. LSC 2014 abstract – Proteinase activated receptor-1 (PAR1) plays a key role in the early inflammatory response to streptococcus pneumoniae pulmonary infection. Eur. Respir. J. 2014; 44 (Suppl. 58): 478.

76. ​Amaro R., Sellar#és J., Riesco J.A. et al. LATE-BREAKING ABSTRACT: Smoking is associated with higher incidence of parapneumonic effusion in community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 318.

77. ​Durmaz F., Coskun A.S., Havlucu Y. et al. Effect of smoking on prognosis and mortality in patients hospitalized due to community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2523.

78. ​S#øgaard M., Madsen M., L#økke A. et al. Incidence and outcomes of hospitalized for COPD exacerbations with and without pneumonia, 2006-2012: A nationwide cohort study. Eur. Respir. J. 2014; 44 (Suppl. 58): 2471.

79. ​Amirova E.F., Farkhutdinov U.R., Kireeva G.M. Community-acquired pneumonia in patients with chronic obstructive pulmonary disease. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 200 (in Russian).

80. ​Dusemund F., Chronis J., Baty F. et al. The outcome of community-acquired pneumonia in patients with COPD, asthma and ILD – a case-control study. Eur. Respir. J. 2014; 44 (Suppl. 58): 2470.

81. ​Marincu L., Bertici N., Mihaicuta S. et al. The prevalence of cardiac diseases in patients with community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2577.

82. ​Aliberti S., Morlacchi L.C., Giuliani F. et al. Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155). Eur. Respir. J. 2014; 44 (Suppl. 58): 485.

83. ​Odintsova D.V., Malyavin A.G., Zayrat'yants O.V. Pneumonia in tanatogenesis of patients with myocardial infarction and stroke. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 205 (in Russian).

84. ​Gouder C., Agius M., Gamoudi D. et al. Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Eur. Respir. J. 2014; 44 (Suppl. 58): 2573.

85. ​Grigor'ev S.P., Krasnovskiy A.L., Zolkina I.V. et al. An influence of inhaled thermoheliox on heart rate variability in patients with community-acquired pneumonia In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 193 (in Russian).

86. ​Costa J., Almeida J., Marques A. Impact of diabetes mellitus on inflammatory markers and severity scales in community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2531.

87. ​Klester E.B., Gervaziev D.V., Proskurin S.N. et al. Lung injury in parenteral drug abusers. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 195 (in Russian).

88. ​Mar#çôa R., Dias M., Coutinho D. et al. Prognostic factors of 30 day mortality in HIV infected patients with community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 254.

89. ​Mar#çôa R., Coutinho D., Dias M. et al. Community-acquired pneumonia in HIV-infected patients: The relevance of CD4+ cell count. Eur. Respir. J. 2014; 44 (Suppl. 58): 4940.

90. ​Van de Garde E., Natsch S., Van der Linden P. Patterns of antibiotic prescribing for pneumonia at the outpatient to inpatient transition. Eur. Respir. J. 2014; 44 (Suppl. 58): 4683.

91. ​Van der Linden P., Natsch S., Van de Garde E. Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4692.

92. ​Ito A., Ishida T., Tachibana H. et al. Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone. Eur. Respir. J. 2014; 44 (Suppl. 58): 4696.

93. ​Kaplan A., Zhanel G., Calciu C. et al. Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZresistant (AZ-R) organisms: Analysis of phase 3 clinical trials. Eur. Respir. J. 2014; 44 (Suppl. 58): 3817.

94. ​Gerasimets E.A. Comparative efficacy of antibacterial treatment of severe community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 199–200 (in Russian).

95. ​Coutinho D., Vaz D., Brito M. et al. Modification of empirical antibiotic therapy in community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2574.

96. ​Chirino A., Peyrani P., Wiemken T. et al. Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 4642.

97. ​Brown K., Chalmers J. Clinicians demonstrate substantial uncertainty in antibiotic management of HCAP and CAP with immunosuppression- a survey study Eur. Respir. J. 2014; 44 (Suppl. 58): 2527.

98. ​Umeki K., Komiya K., Mizukami E. et al. Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Eur. Respir. J. 2014; 44 (Suppl. 58): 2478.

99. ​Shahzad T., Ahmed Khan J., Irfan M. Frequency of multidrug resistant pathogens in healthcare associated pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2526.

100. ​Welte T., Scheeren T.W.L., Rodriguez A. et al. Efficacy of ceftobiprole in intensive care unit (ICU) patients with hospital-acquired pneumonia (HAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 4643.

101. ​Rehman T., Somani V., McGeary C. et al. Inhaled steroids in patients admitted to hospital with pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2554.

102. ​Koehorst-ter Huurne K., Movig K., VanderValk P. et al. Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD? Eur. Respir. J. 2014; 44 (Suppl. 58): 2424.

103. ​Povalyaev D. The efficacy of adjuvant use low molecular weight heparins in patients with community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2503.

104. ​Savsh P.A., Ushakov V.F., Fomin I.V. et al. Systolic and diastolic cardiac function under the surfactant BL therapy of adult patients with viral and bacterial pneumonia at the North. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 212–213 (in Russian).

105. ​Savsh P.A., Ushakov V.F., Fomin I.V. et al. Use of surfactant BL in adult patients with viral and bacterial pneumonia at the North. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 213–214 (in Russian).

106. ​Mirkhaydarov A.M., Farkhutdinov U.R., Farkhutdinov R.R. An influence of Imunovenin on immunologic reactivity in patients with community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 209 (in Russian).

107. ​Mirkhaydarov A.M., Farkhutdinov U.R., Farkhutdinov R.R. Efficacy of Imunovenin in patients with community-acquired pneumonia. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 210–211 (in Russian).

108. ​Bielosludtseva K., Kireeva T. Effectiveness of immune stimulatory therapy in patient with severe community-acquired pneumonia (CAP). Eur. Respir. J. 2014; 44 (Suppl. 58): 2552.

109. ​Nakao S., Tomioka H., Mamesaya N. et al. Clinical features of nursing and healthcare-associated pneumonia in patients who underwent tube feeding. Eur. Respir. J. 2014; 44 (Suppl. 58): 2570.

110. ​Novella L., Sanz F., Fernandez-Fabrellas E. et al. Arterial oxygen content could reflect acute organ damage in community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4647.

111. ​Peiman S., Abtahi H., Yassin Z. Significance of first arterial carbon dioxide pressure in patients hospitalized with community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2578.

112. ​Cilloniz C., Ferrer M., Polverino E. et al. Invasive mechanical ventilation in community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 4932.

113. ​Jinta T., Nishimura N., Ohde S. et al. Clinical application of non-invasive positive-pressure ventilation in patients with community-acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2961.

114. ​Johnson C., Metersky M., Anzueto A. et al. Non-invasive mechanical ventilation and mortality in immunocompromised patients hospitalized with pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 239.

115. ​Vdoushkina E., Chernogayeva G., Povalyaeva L. et al. Noninvasive ventilation support in treatment of pneumonia A (H1N1). Eur. Respir. J. 2014; 44 (Suppl. 58): 2962.

116. ​Ivanov V.Ya. Community-acquired pneumonia in a therapeutic department of a hospital. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 215–216 (in Russian).

117. ​Coutinho D., Oliveira M.J., Mar#çôa A.R. et al. Length of hospital stay in community acquired pneumonia. Eur. Respir. J. 2014; 44 (Suppl. 58): 2513.

118. ​Baldo V., Cocchio S., Saia M. Hospitalization for pneumonia in the Veneto Region (North-East Italy), 2004-2012. Eur. Respir. J. 2014; 44 (Suppl. 58): 1055.

119. ​Wolf K., Bosing M., Misselwitz B. et al. Results of nationwide performance measurement programme for community-acquired pneumonia in German federal state Hessen in 2012. Eur. Respir. J. 2014; 44 (Suppl. 58): 1058.

120. ​Harding L., Davies E., Sundar R. et al. Out of hours vs standard working hour care; a retrospective comparison of pneumonia care. Eur. Respir. J. 2014; 44 (Suppl. 58): 2549.

121. ​Gildeh N., Errington T., Maxwell I. et al. The impact of miscoding of community -acquired pneumonia in a UK district general hospital. Eur. Respir. J. 2014; 44 (Suppl. 58): 204.

122. ​Starchenko A.A., Tarasova O.V., Morozov S.Yu. et al. Criteria of inappropriate antibacterial therapy of nosocomial pneumonia at a governmental insurance system. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 205–206 (in Russian).

123. ​Starchenko A.A., Tarasova O.V., Morozov S.Yu. et al. Criteria of inappropriate antibacterial therapy of hospital-acquired pneumonia at a governmental insurance system. In: The 24th Russian Congress on respiratory disease. Collected scientific papers. Moscow: Dizaynpress; 2014: 206–207 (in Russian).

124.